CLINICAL TRIAL REPORT SIGN-OFF SHEET

Trial title:	A multi-site, Phase I/II, 2-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults
Trial number	BNT162-01
Report type:	Interim
Report version/Date:	3.0 / 20 March 2021

Name, role, affiliation	Date (DD MMM YYYY)	Signature (Hand written)
Sponsor signatories		
Elizabeth Adams, MD, Senior Medical Director, BioNTech US, Inc.	21 Mar 2021	
Stefan Liebscher, PhD, MSc Responsible Statistician, Dr Liebscher Consulting, Germany		

The sponsor signatories confirm that this report i) has been prepared, reviewed, and approved in accordance with the sponsor's standard operating procedures, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, iii) that documentation of this process is filed in the trial master file, and iv) that they approve the document.

Coordinating investigator Dr. Dr. med. Armin Schultz, CRS Clinical Research Services Mannheim GmbH, Germany		

The coordinating investigator confirms i) that he has reviewed the report, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, and iii) that he approves the document.

BIONTECH

TEM-060-039C CTR Sign-Off Sheet

CLINICAL TRIAL REPORT SIGN-OFF SHEET

Trial title:	A multi-site, Phase I/II, 2-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults
Trial number	BNT162-01
Report type:	Interim
Report version/Date:	3.0 / 20 March 2021

Name, role, affiliation	**Date** (DD MMM YYYY)	**Signature** (Hand written)
Sponsor signatories		
Elizabeth Adams, MD, Senior Medical Director, BioNTech US, Inc.		
Stefan Liebscher, PhD, MSc Responsible Statistician, Dr Liebscher Consulting, Germany	21 MAR 2021	S. Liebscher

The sponsor signatories confirm that this report i) has been prepared, reviewed, and approved in accordance with the sponsor's standard operating procedures, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, iii) that documentation of this process is filed in the trial master file, and iv) that they approve the document.

Coordinating investigator Dr. Dr. med. Armin Schultz, CRS Clinical Research Services Mannheim GmbH, Germany		

The coordinating investigator confirms i) that he has reviewed the report, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, and iii) that he approves the document.